Home CD 14++ Monocytes, CD14+/CD16+ Subset and Soluble CD14 as Biological Markers of Inflammatory Systemic Diseases and Monitoring Immuno-suppressive Therapy
Article
Licensed
Unlicensed Requires Authentication

CD 14++ Monocytes, CD14+/CD16+ Subset and Soluble CD14 as Biological Markers of Inflammatory Systemic Diseases and Monitoring Immuno-suppressive Therapy

  • Juergen E. Scherberich and Wolfgang A. Nockher
Published/Copyright: June 1, 2005
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 37 Issue 3

Abstract

The majority of peripheral blood monocytes strongly positive for the lipopolysaccharides (LPS)-receptor CD14 are negative for Fcγ receptor type III (CD16). However, a subset of monocytes coexpressing CD14 and CD16 accounts for about 8% of all monocytes. This population exhibits features of tissue macrophages, and is largely expanded (> 20 %) during acute and chronic inflammatory diseases including cases with pararheumatic systemic vasculitis. In addition, compared to normal controls, soluble CD14 (sCD14) is elevated (> 3 μg/ml) in serum specimens of these patients. CD14+/CD16+ monocytes show a higher phagocytosis rate than CD14+/CD16 negative cells, and express higher levels of interleukin-1 and major histocompatibility complex, such as histocompatibility antigens HLA-DR, -DP and -DQ antigens. Glucocorticoids downregulate expression of CD14 and rapidly deplete CD14+/CD16+ monocytes from peripheral blood. Patients under chronic immunosuppressive therapy exhibit low CD14/+/CD16+ rates, which may rise during infectious and non-infectious inflammatory complications, however. Thus, serial analyses for sCD14 and the proinflammatory CD14+/CD16+ subset of monocytes suggest a valuable tool monitoring patients under immunosuppressive and/or antiinflammatory therapy.

:
Published Online: 2005-06-01
Published in Print: 1999-03-01

Copyright (c)1999 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. IFCC/Beckman European Conference 1998 Frontiers in Molecular Basis of Disease: Inflammatory Diseases
  2. Frontiers in Molecular Basis of Disease: Inflammatory Diseases
  3. Mechanisms of Antigen Presentation
  4. How to Extinguish Lymphocyte Activation, Immunotyrosine-Based Inhibition Motif (ITIM)-Bearing Molecules a Solution?
  5. Association between Reduced Human Leukocyte Antigen (HLA)-DR Expression on Blood Monocytes and Increased Plasma Level of Interleukin-10 in Patients with Severe Burns
  6. Immunostimulatory CpG Motifs Trigger a T Helper-1 Immune Response to Human Immunodeficiency Virus Type-1 (HIV-1) gp160 Envelope Proteins
  7. Activation and Regulation of NFκB during Acute Inflammation
  8. CD 14++ Monocytes, CD14+/CD16+ Subset and Soluble CD14 as Biological Markers of Inflammatory Systemic Diseases and Monitoring Immuno-suppressive Therapy
  9. A Potential Role of an Intracellular Signaling Defect in Neutrophil Functional Abnormalities and Promotion of Tissue Damage in Patients with Localized Juvenile Periodontitis
  10. Polymorphonuclear Oxidative Burst after Helicobacter pylori Water Extract Stimulation Is not Influenced by the Cytotoxic Genotype but Indicates Infection and Gastritis Grade
  11. Flow Cytometry of Cerebrospinal Fluid (CSF) Lymphocytes: Alterations of Blood/CSF Ratios of Lymphocyte Subsets in Inflammation Disorders of Human Central Nervous System (CNS)
  12. Effects of Oxidized Low Density Lipoprotein, Lipid Mediators and Statins on Vascular Cell Interactions
  13. Mycophenolic Acid Influences T Helper 2 (Th2) Cytokine Induced Expression of Intercellular Cell Adhesion Molecule -1 (ICAM-1) on Human Endothelial Cells
  14. Alterations of Endothelial Nucleotide Levels by Mycophenolic Acid Result in Changes of Membrane Glycosylation and E-Selectin Expression
  15. C-Reactive Protein: Structural Biology and Host Defense Function
  16. A Novel Acute-Phase Marker: Lipopolysaccharide Binding Protein (LBP)
  17. Detection of Acute Phase Response and Infection. The Role of Procalcitonin and C-Reactive Protein
  18. Lactoferrin: A Multifunctional Glycoprotein Involved in the Modulation of the Inflammatory Process
  19. Annexin V and Phospholipid Metabolism
  20. Regulation of Leukocyte Trafficking by Lipoxins
  21. Lipoxin and Aspirin-Triggered 15-epi-Lipoxin Cellular Interactions Anti-Inflammatory Lipid Mediators
  22. Differentiation and Assessment of Cell Death
  23. Depending on Their Concentration Oxidized Low Density Lipoproteins Stimulate Extracellular Matrix Synthesis or Induce Apoptosis in Human Coronary Artery Smooth Muscle Cells
  24. Apheresis of Plasma Compounds as a Therapeutic Principle in Severe Sepsis and Multiorgan Dysfunction Syndrome
  25. Supportive Therapy of the Sepsis Syndrome
  26. Supplemental Immune Globulins in Sepsis
  27. Polymorphonuclear Granulocyte Stimulation by Cellulose-Based Hemodialysis Membranes
  28. Reduction of Circulating Cholesterol and Apolipoprotein Levels during Sepsis
  29. Outcome Prediction by Traditional and New Markers of Inflammation in Patients with Sepsis
  30. Isolation of Highly Enriched Human Monocytes from Ten ml Samples of Heparinised Whole Blood
  31. Endotoxin Adsorbant Based on Immobilized Human Serum Albumin
Downloaded on 15.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.1999.039/html?lang=en
Scroll to top button